Vaxcyte financials
$56.69−2.71%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Gross margin | — | — | — | — | — | — |
| Operating income | -$923.7M | -$569.5M | -$468.0M | -$232.3M | -$103.7M | -$89.6M |
| Net income | -$766.6M | -$463.9M | -$402.3M | -$223.5M | -$100.1M | -$89.2M |
| Net margin | — | — | — | — | — | — |
| Diluted EPS | $-5.63 | $-3.80 | $-4.14 | $-3.44 | $-1.93 | $-3.02 |
| EBITDA | -$898.8M | -$553.7M | -$457.9M | -$206.4M | -$100.2M | -$88.2M |
| Operating cash flow | -$655.6M | -$452.6M | -$296.8M | -$170.6M | -$121.4M | -$46.6M |
| Free cash flow | -$712.5M | -$571.8M | -$364.7M | -$176.4M | -$127.9M | -$47.8M |
| Diluted shares | 136.1M | 122.0M | 97.2M | 64.9M | 51.9M | 29.5M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $174.0M | $387.9M | $397.5M | $834.7M | $69.0M | $386.2M |
| Short-term investments | $1.39B | $1.36B | $682.8M | $96.7M | $177.0M | — |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $3.00B | $3.51B | $1.41B | $1.01B | $324.3M | $392.8M |
| Total liabilities | $317.2M | $205.5M | $167.4M | $52.6M | $40.3M | $47.0M |
| Shareholders' equity | $2.69B | $3.31B | $1.24B | $953.6M | $284.0M | $345.8M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology